PLUS THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Indicates management contract or compensatory plan or arrangement.
- Portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv).
† Furnished herewith.
- Schedules and exhibits have been Omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplemental copies of any of the Omitted schedules or exhibits upon request by the Securities and Exchange Commission; provided that the Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
| PLUS THERAPEUTICS, INC. | |
|---|---|
| By: | /s/ Marc H. Hedrick, MD |
| Marc. H. Hedrick, MD | |
| President & Chief Executive Officer | |
| March 12, 2026 | |
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| SIGNATURE | TITLE | DATE |
|---|---|---|
| /s/ Richard J. Hawkins | Chairman of the Board | March 12, 2026 |
| Richard J. Hawkins | ||
| /s/ Marc H. Hedrick, MD | President & Chief Executive Officer (Principal Executive Officer) | March 12, 2026 |
| Marc H. Hedrick, MD | ||
| /s/ Andrew Sims | Chief Financial Officer and VP of Finance (Principal Financial and Accounting Officer) | March 12, 2026 |
| Andrew Sims | ||
| /s/ An van Es-Johansson, MD | Director | March 12, 2026 |
| An van Es-Johansson, MD | ||
| /s/ Howard Clowes | Director | March 12, 2026 |
| Howard Clowes | ||
| /s/ Kyle Guse | Director | March 12, 2026 |
| Kyle Guse | ||
| /s/ Robert Lenk | Director | March 12, 2026 |
| Robert Lenk | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.